Table 2 Overview of clinical trials using BsAbs in patients with LBCL in first line and in R/R setting

First Line

Fit pts

NCT04663347¹

I/II

Epcor + R-CHOP

47

66

(19–82)

LBCL

(IPI ≥ 3)

/

100/87

87/74

at 24 mo (e)

83 CR at 24 mo (e)

60/4.3

27.6

NCT04914741²

II

Glofit-R-CHOP (arm A) vs

Glofit-pola-R-CHP (arm B)

80

58

(24–65)

High risk

LBCL

(IPI ≥ 3, HGBL/

HGBL-double hit)

/

100/70

(arm A) vs

100/80

(arm B)

96/88(arm A) vs 97/95 (arm B)

at 12 mo

NR

20(arm A) vs 22 (arm B)/0

14.6

Older/unfit

NCT05660967³

II

Epcor fixed dose

45

81

(77–95)

LBCL

(age, multiple comorbidities)

/

74/64

76 at 6 mo/NR

88 CR at 6 mo

13/15

6

NCT04663347⁴

I/II

Epcor + R-miniCHOP

28

81

(74–90)

LBCL

(age, cardiological comorbidities)

/

89/82

96/88 at 12 mo (e)

91 CR at 12 mo (e)

45/0

16.8

R/R setting

Monotherapy

NCT02290951-

NCT03888105⁵

I

Odro

187

65

(24–88)

LBCL

Yes

50.8/31.6

27/17.5 at 36 mo (e)

51 at 36 mo

52.9/0

23

NCT03625037⁶

I/II

Epcor

157

64

(20–83)

LBCL, HGBL, mediastinal LBCL

Yes

59/41

18.5 mo /4.2 mo (median)

36.1 mo (median)

51/0

37.1

NCT03075696⁷

II

Glofit

155

66

(21–90)

LBCL

Yes

52/40

77/57 in CR pts

28.9 mo

(median)

62/0

41

NCT02924402⁸

I

Plamo

22

(14 LBCL)

67

(27–90)

LBCL/HGBL/

Other*

Yes

43/14

NR

5.5 mo

(median)

69/9

11

Combination

NCT05364424⁹

I b

Glofit + R-ICE

41

66

(41–78)

LBCL/HGBL

No

78.1/68.8

NR

NR

48.8/0

3#

NCT05283720¹⁰

Ib/II

Epcor + lena

40

71.5

(26–85)

LBCL

Yes

67.6/51.4

NR

NR

65/2.5

11.5

NCT03533283¹¹

Ib/II

Glofit + Pola

57

(LBCL)

59

(29–82)

LBCL/HGBL/

Mediastinal LBCL/transformed FL

Yes

84/61

39.2/12.3 mo

(median *all pts)

31.8 mo

(median *all pts)

43/3.1

23.5

NCT03671018¹²

Ib/II

M -Pola vs

R-Pola

80

(40 vs 40)

71 vs 67

LBCL/HGBL/

Trasformed FL

Yes

78/58 vs 50/35

nr/nr vs

nr/6.4 mo

nr median

4/2.5

18